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ABSTRACT 
Chronic liver diseases are a major health problem. Previous DNA microarray studies of different liver 
diseases have improved our knowledge of the molecular pathogenesis of liver diseases and produced 
potential biomarkers. However, these studies typically rely on binary phenotype comparisons (e.g. cancer 
vs. normal) to identify disease signatures. It is possible that the resulting signatures may be partially 
shared by other liver diseases not included in the binary comparison. In this study, we took a 
comprehensive and organ-specific approach, where we studied all liver pathophysiological states in a 
single unifying context, and found a specific transcriptomic signature for each phenotype with respect to 
all the other phenotypes, instead of just one. The resulting 36-gene disease signature had 85% accuracy 
in 10 fold cross validation. Through stringent leave-one-lab out independent validation, we found that high 
classification accuracy was achieved when there was a total of around 100 samples from 2 independent 
contributing labs. We also identified perturbed networks in liver diseases in general and hepatocellular 
carcinoma in particular. Many of the classifier genes and perturbed networks are involved in important 
biological processes in liver disease pathogenesis, including immune response and inflammation, 
fibrogenesis, metabolism and its regulation, apoptosis, and cellular signaling. The disease classifiers and 
perturbed networks identified in this study may be potential candidates for novel diagnostic approaches to 
multiple liver diseases.  
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CHAPTER 1 
INTRODUCTION 
 
Liver diseases pose a major health threat worldwide. The prevalence of hepatitis C infection is 
approximately 2.2-3.0% (130–170 million people) worldwide [1]. Besides high prevalence, hepatitis C 
shows a higher propensity to yield chronic infection: HCV establishes chronic infection in 60-80% of 
infected individuals [2], making it a major risk factor for chronic liver diseases, especially in western 
countries and Japan. It is estimated that 1% of populations have histological cirrhosis, most of them 
undiagnosed [3]. 80% cases of HCC develop in cirrhotic livers, and cirrhosis is the strongest predisposing 
factor [4]. Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most 
common cause of cancer mortality [5]. It is estimated that there were 564,000 new cases worldwide and 
almost as many deaths in 2000 [6].  
Previous studies of liver transcriptome using DNA microarrays have advanced our understanding of liver 
diseases and yielded potential diagnostic markers [7]. However, these studies rely on binary phenotype 
comparisons (e.g. normal liver vs. cirrhosis, normal liver vs. HCC, cirrhosis vs. HCC) to identify disease 
signatures. It is possible that the resulting signatures may be partially shared by other liver diseases not 
included in each binary comparison. Therefore it is important to take a comprehensive and organ-specific 
approach, where we study all liver pathophysiological states that meet our phenotype and data inclusion 
criteria in a single unifying context, and find a specific transcriptomic signature for a phenotype with 
respect to all the other phenotypes, instead of just one.  
Recently, several classification methods that use the relative expression ordering of only a few genes 
have been developed [8-10]. The decision rules of these methods usually follow this formalism: if a 
particular gene i is expressed higher than another gene j, a sample is classified as class 1; if not, the 
sample is classified as class 2. These methods show comparable accuracy with conventional methods 
such as support vector machines (SVM) while use very simple decision rules that involve small number of 
genes. Since these methods rely only on gene expression ranks, not on the absolute intensities, they are 
invariant to data normalization methods and are free of parameter fitting [8].  
These methods have been extended to deal with multi-class classification problems by integrating with a 
coarse-to-fine search algorithm [11]. In this study, we did a rigorous meta-analysis of available liver 
transcriptomic data to identify disease-specific transcriptomic signatures using this relative-expression 
based method. The disease signatures we identified have 85% classification accuracy in cross validation 
yet involve very few genes (36 unique features).  
As DNA microarrays become widely used, there are many meta-analysis studies that combine data from 
multiple studies to identify robust disease signatures [12]. In a meta-analysis where disease classification 
is the end-point, independent validation is crucial. One previous study found that without any data 
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integration, training classifiers on one data set and testing it on the other independent data set resulted in 
poor classification accuracy [13]. Given the wide-spread differences in sample characteristics, sample 
preparation, hybridization, and other protocol differences between labs, this is not unexpected [14]. In our 
meta-analysis, we did a series of stringent independent validations and found that as long as there are 
around a total of 100 samples from two independent labs to train our classification method, highly 
accurate classification can be achieved on a completely independent data set without any data integration. 
This shows that by combining data from multiple labs in a rigorous way, batch effects would be mitigated, 
robust disease signatures can be identified, and high classification accuracy can be achieved on future 
independent test data.  
Besides accurate disease classifiers, we also identified perturbed networks in liver disease pathogenesis. 
We did two relevant comparisons: one is to compare all liver diseases included in this study (chronic 
hepatitis C, cirrhosis, HCC) with normal liver in order to identify commonly perturbed pathways during 
liver disease pathogenesis in general; the other is to compare HCC with all other non-malignant liver 
phenotypes (normal liver, chronic hepatitis C, cirrhosis) in order to identify perturbed pathways in 
hepatocellular carcinogenesis. We used differential rank conservation (DIRAC) [15], which is also based 
on the relative expression of genes within networks, for this analysis. Many of the classifier genes and 
perturbed networks are involved in important biological processes in liver disease pathogenesis, including 
immune response and inflammation, fibrogenesis, metabolism and its regulation, apoptosis, and cellular 
signaling.  
 
 
 
 
 
 
 
 
 
 
  
3 
 
CHAPTER 2  
 RESULTS 
 
2.1. Microarray data collection and rigorous preprocessing  
We first established our phenotype and data set inclusion criteria. We included phenotypes that have at 
least 20 samples in total and at least two independent contributing labs. All studies should be based on 
Affymetrix microarray platforms to ensure measurement consistency and facilitate data integration. All 
samples should have well-labeled phenotypes. After applying these criteria, we collected 392 microarray 
samples from 7 different studies [16-22]. This data set consists of normal liver, chronic hepatitis C (CHC), 
cirrhosis and HCC (Table 1). We used disease samples of HCV etiology (i.e. they all have persistent HCV 
infection) alone, since samples of varying etiologies would obscures the data and limit the pathogenetic 
insights gained from transcriptomic profiling [2, 23]. We downloaded the raw intensity files of these 392 
samples from Gene Expression Omnibus and used our own microarray consensus preprocessing 
pipeline to process the raw data. This pipeline went through all three different Affymetrix platforms 
(U133A, U133 2.0 and U133 plus 2.0), found common probe sets across platforms, built  a consensus 
platform, used the Matlab (Mathworks, Inc) implementation of GCRMA [24] to preprocess all samples 
together, and used MAS5 detection algorithm [25] to make detection calls (present, absent, marginal). 
After this preprocessing step, we have 22277 probes. We downloaded the most recent Affymetrix official 
probe annotation file (as of April 1, 2011), and removed probes that do not map to any known genes 
according to the latest annotation. After this step, we had 20928 probes. To ensure that a probe is reliably 
detected, we decided that a probe must be present in more than 50% of samples of all 4 phenotypes in 
order to be kept for further analysis. After this step, 9738 probes were kept for further analysis. Our data 
selection, collection, rigorous preprocessing and probe filtering produced a potentially valuable data set 
that can be used by other researchers to identify transcriptomic signatures of various liver diseases. 
2.2. Overview of the data set 
Figure 1, a-c show the principal component plots of the data set after consensus preprocessing and 
probe quality filtering. Four different colors represent different phenotypes, and seven different marker 
shapes represent 7 different experiment batches (batch 1 and batch 2 belong to the same lab).  As shown 
in Figure 1a and Figure 1b, there are two main clusters along the first principal component: batch 7 and 
batch 1-6. Samples in batch 7 (GSE17183) come from a Japanese population, while the rest batches 
mostly consist of Caucasian samples. The separation along the first component is likely due to population 
differences. This poses a serious challenge for chronic hepatitis C, where two populations of comparable 
size exist: 10 Caucasian samples (27.8%) of and 26 Japanese samples (72.2%). In Figure 1c, where the 
second principal component is plotted against the third principal component, there is preliminary 
separation by phenotypes (denoted by four different colors). Our classification method was able to pick up 
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phenotypic signals despite strong non-phenotypic background and achieved high classification accuracy 
even for chronic hepatitis C.  
2.3. Overview of a coarse-to-fine search algorithm for liver disease classification  
We used a method that integrates relative expression reversal with a coarse-to-fine search strategy to do 
multi-disease classification [11]. This method includes three steps (Figure 2). First, for all possible binary 
phenotype combinations, the following score is calculated for each possible gene pair combination: 
∆i,j= �P(Xi > Xj|class 1) −  P(Xi > Xj|class 2)� 
Where P(Xi > Xj|class 1) is the frequency of gene i expressed higher than gene j in class 1 [8]. The gene 
pair that achieves the maximum score is used as the top scoring pair (TSP) for this binary phenotype 
classification. The diagnostic tree construction process is essentially the same as hierarchical clustering, 
where most similar phenotypes are iteratively combined; instead of distance metric, our method uses the 
score of the top scoring pair as the metric for phenotype similarity.  Second, it finds gene pair classifiers at 
each node and branch of the diagnostic tree. Classifiers at each node are used to separate diseases at 
that particular node from all other diseases considered (one vs. the rest); classifiers at each branch are 
used to separate diseases of the left child node from diseases of the right child node (one vs. one) if 
classification ties occur. In classification, a sample of unknown class starts from the root node, and moves 
through classification at each node until it reaches a leaf node(s). If it is accepted at multiple nodes, the 
branch classifier is used to break the tie, since there is only one unique path to a particular leaf starting 
from the root in this diagnostic tree. The benefit of using the node classifier is that a sample can belong to 
none of the liver diseases considered and be rejected at any place in the diagnostic process, while using 
only the branch classifier (a pure decision tree) would force a sample to belong to a unique disease in the 
tree, which may not be desirable.  
2.4. Overview of method to identify deregulated networks in liver pathogenesis 
The Differential Rank Conservation (DIRAC) method [15] assesses combinatorial gene interactions to 
quantify various biological pathways or networks in a comparative sense. This approach is based on the 
relative expression values of participating genes—i.e., the ordering of expression within network profiles 
[15]. Using this method, we identified the most variably expressed networks, representing statistically 
robust differences between disease states at the network level, between all liver diseases and normal 
liver, as well as between HCC and non-malignant phenotypes. Figure 3 describes the overall steps of the 
DIRAC method.  
2.5. Top-Scoring-Pair based decision tree performs highly accurate classification 
To estimate the classification error of this method, we did 10 runs of standard 10-fold cross validation, so 
we can get both the classification accuracy and variance. The probe filtering procedure, where we 
eliminated probes that were absent in more than 50% of samples of any phenotype, was done inside 
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each cross validation loop on the training set only, in order to avoid possible cross talk between training 
and testing samples. Table 2 shows the confusion matrix of classification results. The diagonal elements 
represent correct classifications; the off-diagonal elements represent misclassifications. The average 
accuracy across all classes is 85.2±1.6%, with lowest 72.6±5% (normal liver) and highest 91.7±4.6% 
(chronic hepatitis C). Class-specific accuracy and accuracy variance is shown in Figure 4. It is important 
to notice that the classification accuracy for chronic hepatitis C is much higher than what is possible 
based purely on population difference (27.8% Caucasian vs. 72.2% Japanese), which would only be 72.2% 
at most. To compare this method with other state of the art classification algorithms, we applied Support 
Vector Machines (SVM) on the same dataset. We used the libsvm package [26] for SVM. To ensure a fair 
comparison, the number of features provided in the training set was the same (around 9700, varies in 
cross validation), and the number of features selected by each method in the training set was also the 
same (<=40). The classification results are comparable: SVM achieved average accuracy of 87.7±1.9% in 
10 runs of 10 fold cross validation. The advantage of our method is that it is a parameter-parsimonious 
method that uses very few genes to perform highly accurate multi-class classification, while keeps the 
decision rules straightforward to interpret.  
2.6. Classification performance in independent validation  
Figure 5 shows the result of leave-one-lab-out independent validations. Our data set consists of 7 
different batches from 6 different labs. In each round of leave-one-lab-out validation, we left all samples 
belonging to a lab for testing while trained the classification method on all the other labs. We processed 
training and testing samples separately starting from individual raw intensity files: do GCRMA, probe 
filtering and feature selection only on training labs to ensure truly independent validation. From Figure 5, 
we can observe that when there are reasonably large numbers of samples (~100 samples) from at least 
two different labs, we can get comparable accuracy in independent validation as in cross validation 
(scenario 1). For example, when we when we left out GSE6764, the accuracy for classification remained 
high for both cirrhosis (131 samples in training from 3 labs) and HCC (138 samples in training from 2 
labs), indicating that most of the variance of both phenotypes can be captured by samples in the training 
set. In another scenario where there are too few samples in training, even there are multiple labs, 
classification accuracy is much worse (scenario 2). This is the case for hepatocellular carcinoma when we 
left out GSE9843 (82 samples in training from 2 labs). We almost completely failed when we trained on 
samples from one population and tested on another (scenario 3). This is the case for cirrhosis and 
chronic hepatitis C when we trained on Caucasian samples and tested on samples from a Japanese 
population (GSE17183) or vice versa.  
The classifiers presented in our study are based on training on the whole data set. Classification for 
cirrhosis and hepatocellular carcinoma resembles scenario 1, while classification for normal liver and 
chronic hepatitis C resembles scenario 2. Based on observations from independent validations, we have 
good confidence in classifiers related to cirrhosis and hepatocellular carcinoma, and modest confidence 
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in classifiers related to normal and chronic hepatitis C. As microarrays become widely used in hepatology 
research, we anticipate that there will be more samples for each major liver pathophysiological state, and 
disease classifiers produced by our method would be more and more accurate in independent validations 
given greater availability of these high throughput data. 
2.7. Classifier genes are closely involved in liver disease pathogenesis 
Through literature search, we found that many genes in our classifier are involved in important biological 
processes (immune response and inflammation, fibrogenesis, metabolism, and cellular signaling) of liver 
disease pathogenesis and their up or down regulation in a particular disease may have a mechanistic 
explanation. Classifier genes information is shown in Table 3. Genes with literature evidence of potential 
involvement in liver disease are listed in Table 4.  
HLA-B, FAM21, EDEM1, UBD and CD74 reflect the presence of hepatitis C infection. Higher expression 
of HLA-B and CD74 in patients infected with HCV may reflect hosts' immune response to persistent viral 
infection. CD74's ligand, MIF (macrophage migration inhibitory factor) has a wide range of functions that 
links inflammation to carcinogenesis: it suppresses immunosurveillance [27], contributes to 
neoangiogenesis and epithelial cell proliferation [28], and suppresses p53 function [29]. Serum level of 
MIF has been reported to be elevated in HCC and liver cirrhosis patients [30]. Its overexpression is also 
associated with poor prognosis in HCC patients [31]. Our meta-analysis showed that higher expression of 
MIF's cognate receptor CD74 may be a possible mechanism that this cytokine exerts its effects in liver 
disease pathogenesis. EDEM1 is directly involved in endoplasmic reticulum-associated degradation 
(ERAD), and its transcription is inhibited by HCV non-structural protein 4B (NS4B) [32], which may 
explain its lower expression in liver disease patients. UBD is negatively regulated by p53 [33], and it has 
been reported that HCV core protein relieves p53-mediated suppression [34], which may explain UBD's 
higher expression in liver diseases of HCV etiology. 
AGRN, COL4A1, and ADAMTSL3 may participate in the fibrogenesis process characteristic of liver 
diseases. As a result of bile ductules proliferation and new blood vessels formation in liver cirrhosis as 
well as neoangiogenesis in HCC, there is a drastic increase in the quantity of AGRN in HCC and liver 
cirrhosis [35]. Type IV collagen can stimulate resident hepatic stellate cells, a major collagen producer in 
liver fibrosis, by activating latent cytokines such as TGF-beta1 [36]. Both plasma and hepatic level of type 
IV collagen peptide have been reported to be elevated in chronic hepatitis C and cirrhosis patients [37-39]. 
ADAMTSL3 is a member of the ADAMTS family of proteins. ADAMTS proteins are known to be involved 
in collagen processing, cleavage of the matrix proteoglycans, and anti-angiogenesis [40]. ADAMTSL3 is 
located in the extracellular matrix, and may be involved in cell-matrix interactions or assembly of specific 
extracellular matrices [41].  
ACAT1, DUT, MT1G, GLRX5, and AGPAT1 are involved in different aspects of metabolism that may be 
related to liver disease pathogenesis. As HCV infection results in increased fatty acid synthesis [42] and 
inhibition of fatty acid oxidation [43], the reduced expression of ACAT1 in liver diseases of HCV etiology 
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may reflect hosts' response to decreased demand of ketone body metabolism. DUT encodes an essential 
enzyme of nucleotide metabolism that hydrolyzes dUTP to dUMP, a precursor for the synthesis of 
thymine nucleotides needed for DNA synthesis. DUT upregulation may be the result of hepatocyte 
regeneration in chronic hepatitis C and cirrhosis, and tumor cell proliferation in HCC, both of which 
require DUT activity for increased DNA synthesis relative to resting hepatocyte in healthy liver. MT1G 
binds to heavy metals and reduces cellular oxidative stress by capturing harmful oxidant radicals like the 
superoxide and hydroxyl radicals [44]. A significant inverse correlation between MT protein or mRNA 
expression and both the grade and the stage of fibrosis has been reported [45]. Its expression is 
significantly decreased in HCC and hepatoblastoma as a result of promoter hypermethylation [46, 47]. 
GLRX5 is a member of the glutaredoxins that maintain the cellular redox state, serving as essential 
protein antioxidants [48]. GLRX5 deficiency in human is characterized by anemia and iron overload [49]. 
In the liver, excess iron acts as a pro-inflammatory agent and is associated with increased morbidity and 
mortality of HCV related chronic liver disease [50]. Down-regulation of these two redox-balancing proteins 
may thus exacerbate the increased cellular oxidative stress caused by HCV [51] and contribute to 
disease progression. AGPAT1 converts lysophosphatidic acid (LPA) to phosphatidic acid (PA) [52]. The 
bioactive LPA is a potent mediator of tissue repair and wound healing [53, 54], and wound healing is a 
characteristic process in liver fibrosis and cirrhosis as a result of chronic liver injury afflicted by HCV [55]. 
While LPA increased DNA synthesis and MAP kinase activity in hepatic stellate cells, the major player in 
liver fibrogenesis, it decreased DNA synthesis in hepatocytes [56]. AGPAT1's lower expression in 
cirrhosis relative to HCC may reflect LPA's decreased conversion to PA and increased involvement in the 
fibrogenesis process; while its higher expression may reduce LPA level in HCC, and LPA has a negative 
effect on hepatocyte proliferation.  
TACSTD2, MAPKAPK2, ADIPOR1, ALPL, ENDRB, and ANXA3 may participate in various cellular 
signaling events that may contribute to liver disease pathogenesis. TACSTD2’s higher expression in 
cirrhosis relative to HCC may reflect the oval cell activation event in liver cirrhosis [57]. MAPKAPK2's 
higher expression in HCC relative to cirrhosis may contribute to HCC invasion. ADIPOR1 encodes a 
receptor for adiponectin, a protein hormone that modulates a number of metabolic processes, including 
glucose regulation and fatty acid catabolism [58]. Interestingly, in a 9-year follow-up study, chronic 
hepatitis C and cirrhosis patients with higher serum adiponectin had a higher incidence of developing 
HCC [59]. EDNRB encodes a non-specific receptor for endothelin 1, 2, and 3. Its relative expression in 
cirrhosis and HCC is consistent with our meta-analysis result.  ANXA3 have been identified as a potential 
angiogenic factor that induces VEGF production through HIF-1 pathway [60], and is induced during 
hepatocyte regeneration, a characteristic process in cirrhotic nodules [61].  
From the above discussion, we can see that many genes in our classifier have clear concrete links to liver 
disease pathogenesis and our method identified these genes as accurate disease classifiers without any 
prior knowledge.   
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2.8. Perturbed pathways in liver diseases 
Using differential rank conservation method, we did two comparisons: all liver diseases vs. normal live 
(Table 5), and HCC vs. non-malignant liver phenotypes (Table 6). The first comparison is to identify 
commonly perturbed pathways in liver disease pathogenesis, and the second comparison is to identify 
perturbed pathways in hepatocellular carcinogenesis.  
The commonly perturbed pathways in liver diseases identified in our analysis have been previously 
implicated in liver disease pathogenesis. The CXCL12/CXCR4 pathway is implicated in recruiting liver 
infiltrating lymphocytes [62] and is the key player in HCV-associated liver inflammation and fibrosis [63]. 
EGF up-regulation is a characteristic event in both cirrhotic liver disease and HCC [64, 65], and there is 
mounting evidence supporting its role in linking inflammation caused by chronic liver injury like HCV 
infection, liver fibrosis, and cancer [66]. The mTOR pathway plays a pivotal role in HCC [67] and links 
inflammation to tumor angiogenesis [68]. Aberrant mTOR signaling in liver is associated with both IGF1 
and EGF pathway activation [67], both of which are also listed among the top 10 perturbed pathways. 
Both the HIVNEF and the TNFR1 pathways may be related to the ability of HCV core protein to inhibit 
apoptosis mediated by Fas-L and tumor necrosis factor alpha [69, 70]. HCV is known to impair insulin 
signaling and induce insulin resistance by down-regulating two key components in this pathway: IRS1 
and IRS2 [71], and provides a mechanistic explanation for increased prevalence of type 2 diabetes in 
chronic hepatitis C patients [72]. Both the PLATELETAPP pathway and the INTRINSIC pathway are both 
involved in blood coagulation. The liver plays a central role in the blood coagulation process as the major 
synthesis site for coagulation factors, and acute and chronic liver diseases are invariably associated with 
coagulation disorders [73].  
Among the top 10 variably expressed pathways between HCC and non-malignant phenotypes, the 
integrin and the extracellular matrix (ECM) signaling pathways are ranked 1st and 10th respectiviely, 
pointing out the crucial role of tumor microenvironment in hepatocellular carcinogenesis. The fibrotic 
microenvironment in the liver is characterized by an altered composition of the extracellular matrix (ECM), 
and key components of the integrin and ECM signaling are crucial regulators of HCC invasion [74]. The 
MAPK pathway is activated by multiple growth factors and its increased activation in HCC has already 
been identified [75]. The serum level of IL-6, a pro-inflammatory cytokine,  is significantly higher in HCC 
compared to cirrhosis and control [76]. Both liver injury and compensatory proliferation were strongly 
dependent on IL-6 and that the absence of this tumor promoting cytokine resulted in almost complete 
inhibition of DEN-induced hepatocarcinogenesis [77]. According to Biocarta pathway definition, the HER2 
partway consists of components from the IL-6 signaling pathway, the ERK pathway, and the AKT 
pathway, all of which play crucial roles in hepatocellular carcinogenesis. Therefore, the HER2 pathway 
may reflect the synergistic effects of these three pathways. The c-MET pathway mediates the signaling of 
hepatocyte growth factor (HGF), a potent mitogen for hepatocytes. This c-MET is overexpressed in HCC, 
and higher expression is associated with poor 5-year survival [78].  
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It is interesting to notice that many classifier genes and the variably expressed pathways point to similar 
biological processes in liver disease pathogenesis. HLA-B and CD74 are involved in immune response to 
hepatitis C virus and ensuing inflammation and carcinogenesis; the CXCR4 and IL-6 pathways also 
participate in this process. AGRN, COL4A1, and ADMATSL3 are either basement membrane 
components or mediate cell-matrix interaction important in liver fibrosis; the integrin and ECM signaling 
pathways also participate in this process. COL4A1 is also part of the PLATELETAPP pathway and the 
INTRINSIC pathway, both of which are commonly perturbed in liver diseases. ACAT1, DUT, and AGPAT1 
are involved in fatty acid, nucleotide, and phospholipids metabolism respectively; signaling through the 
IGF-mTOR pathway results in decreased fatty acid oxidation [79], increased lipid synthesis [80], and DNA 
synthesis. MAPKAPK2 is a downstream target of the MAPK pathway, which is ranked as the 4th variably 
expressed pathway between HCC and non-malignant liver phenotypes.  
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2.9. Tables 
Table 1. Dataset and phenotype sample distribution 
 
Phenotypes 
sum 
Normal CHC Cirrhosis HCC 
G
E
O
 a
cc
es
si
on
 
GSE14323 19 0 58 47 124 
GSE17967 0 0 63 0 63 
GSE6764 10 0 13 35 58 
GSE9843 0 0 0 91 91 
GSE11190 2 10 6 0 18 
GSE14668 8 0 0 0 8 
GSE17183 0 26 4 0 30 
sum  39 36 144 173 392 
CHC: chronic hepatitis C; HCC: hepatocellular carcinoma 
 
Table 2. Confusion matrix of classification performance 
  
Predicted disease classes 
Normal CH HCC CHC 
A
ct
ua
l d
is
ea
se
 
cl
as
se
s 
Normal 72.6% 3.8% 18.5% 5.1% 
CH 0.2% 91.0% 4.9% 4.0% 
HCC 0.1% 14.0% 85.5% 0.5% 
HCV 3.1% 2.5% 2.8% 91.7% 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C 
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Table 3. Classifier genes information 
a. List of node-based classifier genes 
Disease 
gene i gene j 
gene symbol probe gene symbol probe 
CH,HCC,CHC 
HLA-B 209140_x_at ACAT1 205412_at 
FAM21 212370_x_at EDEM1 203279_at 
PBXIP1 214177_s_at ADAMTSL3 213974_at 
 UBD 205890_s_at SLC17A2 207097_s_at 
AGRN 212285_s_at ALPL 215783_s_at 
DUT 209932_s_at MFAP3L 205442_at 
CD74 209619_at MT1G 204745_x_at 
CH,HCC 
COL4A1 211980_at ASH2L 209517_s_at 
STX16 221499_s_at TMEM57 218562_s_at 
CAP1 200625_s_at GLRX5 221932_s_at 
CHC FAM149A 214890_s_at DHX40 218277_s_at 
CH 
CLDN10 205328_at AGPAT1 32836_at 
TACSTD2 202286_s_at HGS 210428_s_at 
EDNRB 206701_x_at PPP2R5D 202513_s_at 
GPM6A 209469_at FLAD1 205661_s_at 
ANXA3 209369_at MAPKAPK2 201461_s_at 
SH3YL1 204019_s_at ADIPOR1 217748_at 
MYO10 201976_s_at MRPL2 218887_at 
HCC 
AGPAT1 32836_at CLDN10 205328_at 
HGS 210428_s_at TACSTD2 202286_s_at 
PPP2R5D 202513_s_at EDNRB 206701_x_at 
FLAD1 205661_s_at GPM6A 209469_at 
MAPKAPK2 201461_s_at ANXA3 209369_at 
ADIPOR1 217748_at SH3YL1 204019_s_at 
MRPL2 218887_at MYO10 201976_s_at 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C 
 
b. Branch-based classifier information 
Disease separation gene i probe i gene j probe j 
CH,HCC vs. CHC DHX40 218277_s_at FAM149A 214890_s_at 
CH vs. HCC CLDN10 205328_at AGPAT1 32836_at 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C 
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Table 4. Genes with literature evidence of potential involvement in liver disease 
Gene 
symbol Involvement in liver disease Reference 
HLA-B antigen presentation; higher expression in HCC  [81] 
CD74 antigen presentation; receptor for macrophage migration inhibitory factor  [82, 83] 
EDEM1 targets misfolded glycoprotein for degradation; inhibited by HCV NS4B  [32, 84] 
UBD overexpressed in HCC; contributes to genome instability  [85, 86] 
AGRN liver basement membrane component, accumulated in cirrhosis and HCC  [35] 
COL4A1 liver basement membrane component; elevated level associated with liver fibrosis  [37-39, 55] 
ADAMTSL3 highly expressed in liver; extracellular matrix component  [41] 
ACAT1 catalyzes formation of acetoacetyl-CoA, key step in ketone metabolism  [87] 
DUT1 overexpressed in proliferating hepatomas; associated with poor survival in HCC  [88, 89] 
MT1G reduces oxidative stress; down-regulated in HCV-infected patients and HCC  [44-46] 
GLRX5 redox balance; deficiency results in iron overload, a risk factor for liver disease  [48-50] 
AGPAT1 converts lysophosphatidic acid, a stimulator of wound healing, to phosphatidic acid  [52, 53] 
TACSTD2 marker for hepatic oval cell, a facultative hepatic stem cell type  [90] 
MAPKAPK2 activated by MAPK, involved in cancer cell invasion  [91-93] 
ADIPOR1 receptor for adiponectin, a risk factor for developing HCC   [59, 94, 95] 
ALPL increased serum level reflects malignant infiltration in liver  [96] 
ENDRB overexpressed in cirrhosis; reduced in HCC due to promoter hypermethylation  [97-99] 
ANXA3 potential angiogenic mediator; increased expression in liver regeneration  [60, 61] 
  
13 
 
Table 5. Variably expressed networks between liver diseases and normal liver 
Network name Num.genes Num.gene pairs Apparent accuracy p-value 
CXCR4_PATHWAY 17 136 0.915 <7E-07 
EGF_PATHWAY 21 210 0.908 <7E-07 
HIVNEF_PATHWAY 41 820 0.9 <7E-07 
IGF1MTOR_PATHWAY 17 136 0.879 <7E-07 
INTEGRIN_PATHWAY 25 300 0.878 <7E-07 
IGF1_PATHWAY 16 120 0.874 <7E-07 
TNFR1_PATHWAY 20 190 0.874 <7E-07 
PLATELETAPP_PATHWAY 9 36 0.868 <7E-07 
INTRINSIC_PATHWAY 19 171 0.867 <7E-07 
INSULIN_PATHWAY 16 120 0.865 <7E-07 
 
Table 6.Variably expressed networks between HCC and non-malignant phenotypes 
Network name Num.genes Num.gene pairs Apparent accuracy p-value 
INTEGRIN_PATHWAY 25 300 0.84 <7E-07 
HER2_PATHWAY 17 136 0.83 <7E-07 
EDG1_PATHWAY 17 136 0.825 <7E-07 
MAPK_PATHWAY 54 1431 0.823 <7E-07 
IGF1R_PATHWAY 18 153 0.821 <7E-07 
MET_PATHWAY 22 231 0.818 <7E-07 
IL6_PATHWAY 17 136 0.817 <7E-07 
CXCR4_PATHWAY 17 136 0.815 <7E-07 
AT1R_PATHWAY 23 253 0.814 <7E-07 
ECM_PATHWAY 18 153 0.813 <7E-07 
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2.10. Figures 
Figure 1.Principal component plots of processed dataset  
1.a. 1st vs. 2nd 
 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C; N: normal liver 
  
Japanese samples 
Caucasian samples 
15 
 
1.b. 1st vs. 3rd 
 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C; N: normal liver 
  
Japanese samples 
Caucasian samples 
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1.c. 2nd vs. 3rd 
 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C; N: normal liver 
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Figure 2. Diagnostic tree construction, deification of node and branch based classifiers, and classification 
of sample 
 
The diagnostic tree is constructed through an essentially hierarchical clustering approach where the score of the top scoring pair is 
used as a similarity metric. The top scoring pair at each branch and the binary outcome of each phenotype at each branch is 
accumulated into a barcode panel, where each phenotype has a unique binary signature. The barcode panel is used to resolve ties 
in classification. Classifiers at each node are used to decide if a sample belongs to the phenotypes at that node based on an optimal 
threshold. Normal liver is the default classification class. It is not used in tree construction, but used as a negative set to train 
classifiers for the "Diseases" node. As illustrated in the figure, the hypothetical sample would be accepted at the "Diseases" node 
since it passed the vote threshold, and proceeds to both the "CH, HCC" node and the "CHC" node. It would be rejected at the 
"CHC" node since it did not pass the vote threshold at that node.  
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Figure 3. Overview of the Differential Rank Conservation (DIRAC) methods. Adopted with permission 
from Eddy et al [15]. 
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Figure 4. Disease classification accuracy and variance in 10 runs of 10 fold cross validation 
 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C 
 
Figure 5. Leave-one-lab out independent validation results 
 
CH: cirrhosis; HCC: hepatocellular carcinoma; CHC: chronic hepatitis C 
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CHAPTER 3 
 CONCLUSION 
 
In this study, we collected, processed and analyzed 392 microarray samples of 4 liver pathophysiological 
states from 7 published studies. We took a comprehensive approach to consider all 4 major liver 
pathophysiological states in a single unified context, and identified specific transcriptomic signatures for 
each phenotype. Based on gene pairs whose relative orderings are most informative of phenotype 
distinction, we built a coarse-to-fine diagnostic tree from bottom up, which performed classification at 
each node and leaf of the tree. Our classifier consists of 36 unique features, and has 85.2±1.6% average 
accuracy across 10 runs of 10 fold cross-validation. Our classifier has comparable accuracy with SVM 
(87.7±1.9%), when both methods used the same number of features for training, and selected similar 
number of features in their respective classifiers. The main advantage of our method is that it is a data-
driven, parameter-parsimonious method that requires little tuning from the user.  Classification is based 
on relative ranking of gene expression values, not absolute intensities, thus this method is invariant to 
normalizations that preserve relative ordering of genes. Another benefit is that it produces more 
interpretable classifiers (a list of "gene i expressed higher than gene j " in each disease) than SVM, and 
may be more conducive to production of diagnostic tests.  
We did stringent leave-one-lab out independent validations to validate our method, and found that as long 
there are samples from two independent labs with reasonable total sample size (around 100 samples) to 
train our classification method, highly accurate classification can be achieved on a completely 
independent test data set without any data integration. This is probably because accurate classifiers 
trained from two independent labs captured the true characteristics of the phenotype, instead of any 
particular lab. There are many data sets on Gene Expression Omnibus that studied the same disease on 
same or similar platforms (e.g. Affymetrix U133A, U133 2.0 or U133 Plus 2.0), and more data sets will be 
available with the wide-spread use of DNA microarray and other high throughput technology like RNA-seq. 
The results of our independent validations suggest that properly integrating samples from multiple 
sources may be a potentially useful way to mitigate the lab or batch effects inherent in these high 
throughput data. 
We found that many genes in our classifier are involved in important biological processes of liver disease 
pathogenesis. They participate in immune response, inflammation, oxidative stress response, 
fibrogenesis, and metabolism. Many genes' relatively higher or lower expression in a particular phenotype 
can be explained by mechanisms such as direct inhibition by HCV proteins, indirect activation by HCV 
proteins, and promoter hypermethylation. Using a new method developed in our lab, we also identified 
commonly perturbed networks in liver diseases compared to normal liver, and perturbed networks in HCC 
compared to non-malignant phenotypes. We were able to identify networks known to play important roles 
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in liver disease pathogenesis: CXCR4, mTOR, epidermal growth factor, insulin growth factor 1, and 
apoptosis-related signaling networks. These pathways link immunity, inflammation, fibrosis, metabolism 
and malignant transformation. Perturbed networks in HCC reflected two important players in 
hepatocarcinogenesis: dysregulation of growth factor signaling (EGF, MAPK, IGF, and MET) [100] and 
tumor microenvironment (integrin and ECM signaling) [101]. Both the classifiers and the perturbed 
pathways identified in this study offer biological insight into the pathogenesis of liver diseases, and may 
be potential candidates for novel diagnostic approaches to multiple liver diseases. 
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CHAPTER 4 
 METHODS 
 
4.1. Building a coarse-to-fine diagnostic tree and identifying branch-based classifiers 
Let E be a P×N matrix of P genes and N samples. Let C= {C1, C2,...CM} be the set of possible class labels. 
In this study, there are 4 phenotypes, so M=4. C4 represent normal liver, the default class a sample would 
be classified, and would not be in the iterative tree-building process.  First, we rank the gene expression 
values within each sample. After this step, the absolute expression intensities are replaced by relative 
orderings, the expression matrix E becomes a rank matrix X. Let Pij(Cm) = Pr( Xi > Xj | Y = Cm) be the 
possibility of observing Xi > Xj (the expression level of gene i is higher than that of gene j) in class Cm. 
Pij(Cm) is estimated by the frequency of observing Xi > Xj in class Cm. Let Δij = |Pij(C1) - Pij(C2)| be the 
score of each gene pair (i, j), which quantifies the difference in probability of observing Xi > Xj between 
class 1 and class 2. A score of 0 means that the ordering Xi > Xj is equally likely in both classes, and the 
relative ordering of gene pair (i, j) is not informative of class distinction; a score of 1 means we always 
observe Xi > Xj in class 1 and never in class 2, and the relative ordering of gene pair (i, j) is highly 
informative of class distinction. The higher the score, the better gene pair (i, j) can classify class 1 and 2. 
The score of the gene pair that can most accurately classify class 1 and 2 is denoted as Δmax, and the 
gene pair is called "top scoring pair" (TSP) [8]. To reduce our search space and avoid potential over-fitting, 
we selected the top 2500 differentially expressed genes with Wilcoxon rank sum test inside cross 
validation for TSP calculation. The calculation of TSP from around thousands of genes, representing 
millions of possible binary combinations is a computationally intensive yet parallelizable task. Therefore, 
we used the GPU-implementation of TSP calculation which resulted in dramatic speedup [102]. 
Building the coarse-to-fine diagnostic tree is the same as hierarchical clustering, where the most similar 
phenotypes are iteratively combined to form a new node, and the score of the top scoring pair is used as 
the similarity metric. The top scoring pairs at each bifurcation of the diagnostic tree are accumulated into 
a barcode panel, where each disease class has a unique binary signature recording the outcome of 
whether Xi > Xj at each bifurcation of the tree. 
4.2. Identifying node-based classifiers  
The major difference our diagnostic tree and a pure decision tree is that classification happens at the 
nodes of the tree, not at the branches (bifurcations). In a pure decision tree, once a sample is inside the 
tree, it is forced to go to a unique leaf. However, in our diagnostic tree, starting from the root, a sample 
will go to both child nodes of the current node, and can be accepted at neither of the child nodes, either of 
the child nodes, or both of the child nodes. The branch-classifiers are only used when there are multiple 
diagnosis: a sample is accepted at multiple leaves of the diagnostic tree. The advantage of this feature is 
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that even a sample is inside our diagnostic tree, it can still be rejected at any node of the tree, and does 
not have to be diagnosed as one of the classes inside the tree. The basis of this important feature is the 
classifiers at each node of the diagnostic tree. 
When identifying the node-based classifiers, we already have the structure of the diagnostic tree. At each 
node, there is a positive and a negative set: positive set is the set of classes belonging to that node, 
negative set is the set of classes whose members reach that node yet do not belong to the positive set. 
This is possible because samples may be misclassified at the previous nodes and make to both of the 
child nodes. At the root node, the positive set is all 3 liver diseases, and the negative set is normal liver. 
Let x = (1, 3, 5, 7, 9 ) be the maximum possible number of top scoring gene pairs (not only the best gene 
pairs, but the 2nd best, 3rd best, and so on) to be used classify the positive set and negative set. Let K be 
the number of top scoring pairs actually used. Let k be the number of "votes" a sample needs in order to 
be accepted at that node (k ≤ K ≤ x ). An internal cross-validation loop is performed to identify the optimal 
K and k for each node that maximize classification sensitivity.   
4.3. Classification of microarray samples 
Classification starts at the root node, and proceeds to both of the child nodes. Let µ denote the number of 
votes (how many times Xi > Xj is true for that sample for all K top scoring pairs used at that node) a 
sample gets. If µ < k (the threshold), then the sample would be rejected, and classified as the default 
class: normal liver. If µ ≥ k, the sample would be accepted at the current node, and proceeds to both of its 
child nodes. The previous process is repeated until the sample reaches a leaf (leaves). If the sample is 
accepted at multiple leaves, the branch-based classifiers, which essentially form a pure decision tree, are 
used to break the tie. Since there is only one unique path from the root to any leaf, a unique single 
diagnosis is guaranteed.  
4.4. Identifying perturbed networks 
All steps described in this part is based on the original DIRAC method [15].  
First, we downloaded network definitions from Biocarta (Mar 30, 2011). Given the list {g1, ..., gGm} of Gm 
genes within a network m on a microarray, let X  denote the corresponding expression profile, where Xi is 
the expression profile of gene gi. Our microarray data then consists of a Gm ×N matrix; the nth column 
represents the expression profile xn of the nth sample, n=1, ..., N. In addition, each sample is labeled by a 
phenotype k ∈ C={C1,C2,...CK}. In our case, M=4. DIRAC is based entirely on the ranks within each 
expression profile. For a network of Gm genes, it considers all Gm (Gm -1)/2 possible orderings of all gene 
pairs. For example, if there are =4 genes, then there are six distinct ordered pairs: {(1, 2)}, {(1, 3)}, {(1, 4)}, 
{(2, 3)}, {(2, 4)}, {(3, 4)}.  
Rank template matching for networks. In this step, we define a template representing the expected 
ranking of network genes within a phenotype. We consider P(Ck) = Pr( Xi > Xj | Y = Ck) for each pair of 
genes (i, j) of network m, and all phenotype Ck. We estimate these probabilities by the observed 
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frequency of Xi < Xj (the expression level of gene i is higher than that of gene j) in class Ck. The rank 
template for a fixed network m and phenotype Ck is the binary vector T(m, Ck) of length Gm (Gm -1)/2 where 
the  i, jth component is 1 if  P(Ck) >0.5 and 0 if   P(Ck) <0.5. Given a sample's expression profile xn for the 
network m, rank matching score R(m, Ck)( xn) measures how well the sample matches the template T(m, Ck). 
R(m, Ck)( xn) is defined to be the fraction of the Gm (Gm -1)/2 pairs for which the observed ordering within xn 
matches the template: the expected ordering for phenotype Ck.  
Rank difference scores. Rank difference is defined as Δ(m)( xn) = R(m, Ck1)( xn) - R(m, Ck2)( xn), that is, the 
difference between the rank matching score when sample n is matched to the rank template of phenotype 
Ck1 and the rank matching score when sample n is matched to the rank template of phenotype Ck2. 
Clearly, -1≤ Δ(m)( xn)  ≤1 with positive values providing evidence that the phenotype of sample n is Ck1 
and negative values providing evidence that the phenotype of sample n is Ck2. Therefore, the difference 
score provides a classifier for phenotype identification based on the degree of regulation of the genes in 
network m: phenotype Y= Ck1 if Δ(m)( xn) >0 and phenotype Y= Ck2 if Δ(m)( xn) ≤ 0.  A good network 
classifier would have the following property: the variance of R(m, Ck1)( xn) of all samples belonging to 
phenotype Ck1 and the variance of R(m, Ck2)( xn) of all samples belonging to phenotype Ck2 are both small; 
the difference between rank templates T(m, Ck1) and T(m, Ck2) is big. In other words, the rank matching 
scores for this network have low variance within each phenotype, but high variance across phenotypes. 
Networks with such properties are called "variably expressed networks", and represent statistically robust 
differences between phenotypes. The accuracy of the network classifier m is defined as the average 
sensitivity and specificity of identifying relevant phenotypes.  
Significance testing for the classification rate of variably expressed networks. After identifying variably 
expressed networks between two phenotypes based on their ability to accurately classify samples, a 
permutation test is used to evaluate the significance of these networks. Under the null hypothesis that no 
systematic difference in gene expression profiles exist between Ck1 and Ck2, (i) the original sample labels 
were randomly re-assigned to samples, while keeping the number of samples belonging to each 
phenotype same as the original data set; (ii) sample classes in the permuted data set were predicted as 
Ck1 or Ck2 based on whether the rank difference score was positive or negative, respectively, and scores 
were assigned to each network as measured by the estimated classification accuracy; (iii) the first two 
steps were repeated for 10,000 permutations to generate a null distribution of network classification rates; 
and (iv) the significance level for the classification accuracy of network m was measured as the probability 
of observing classification rates greater than or equal to the original classification accuracy in the null 
distribution.  
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